A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis
Details
Age
Child
Type of Study
Treatment
Locations
Childrens Hospital Colorado
Principal Investigator
Anna Bruckner, MD
Study ID
Protocol Number: 22-0741
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers